Accelerating process development for biologics on an automated, pharmacy-scale manufacturing system
Name
1193321397-MIT.pdf
Size
3.82 MB
Format
Adobe PDF
Checksum (MD5)
762f0c57e9fc5afafdf88497cb711e84
Author(s)
Crowell, Laura E.(Laura Ellen)
Advisor(s)
J. Christopher Love.
Date Issued
2019
Publisher
Massachusetts Institute of Technology
Abstract
The conventional large-scale, centralized, single-product manufacturing model for biologic drugs does not allow for the economical production of drugs for small patient populations or for the distribution of these drugs in developing countries. A decentralized model featuring small-scale, fully automated, multi-product manufacturing of biologics at the point-of-care could address some of these issues. To truly realize the benefits of such a manufacturing paradigm, it must also be paired with rapid process development methods for the production of new molecules. In this thesis, we describe the development of a bench-scale, automated, multi-product manufacturing system for the end-to-end production of hundreds to thousands of doses of clinical quality protein medicines in about three days. We then demonstrate the application of this platform to the manufacture of a trivalent vaccine in a single campaign through co-expression and co-purification.
We further demonstrate new methodologies for the accelerated development of manufacturing processes to produce new molecules on the system including a strategy for the development and optimization of fully integrated, multi-column processes for straight-through chromatographic purification, and the development of a platform process for the production and purification of single-domain antibodies. We then propose a workflow for the collection of a dataset relating the chromatographic behavior of host-cell proteins to their biophysical characteristics with the goal of building an in silico tool for the prediction of purification processes for any new molecule. Finally, we propose a platform approach, as opposed to a platform process, for the development of manufacturing processes for new biologics which is based on gaining a deeper understanding of process development challenges with regard to the host and to the molecule itself.
Ultimately, we believe that the combination of a small-scale, automated manufacturing platform and accelerated strategies for developing processes to manufacture new products on the platform could enable time- and cost-efficient manufacturing of a wide variety of biologic drugs, increasing access to medicines throughout the world.
Description
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Chemical Engineering, May, 2019
Cataloged from the official PDF of thesis.
Includes bibliographical references (pages 157-166).
Subjects
Chemical Engineering.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
MIT theses may be protected by copyright. Please reuse MIT thesis content according to the MIT Libraries Permissions Policy, which is available through the URL provided.
Persistent DSpace Link
